Although not currently used to guide standard treatment, the expression of PD-L1 in hormone-receptor-positive BC remains an area of continuous research due to the potential benefits of combining endocrine or targeted therapies with immune checkpoint inhibitors such as atezolizumab and pembrolizumab to overcome resistance and improve clinical outcome [23]. The gene discussed is NR4A1; the disease is breast cancer.